Moderna to seek regulatory approval for COVID shot for very young children
By Trend
Moderna Inc (MRNA.O) said on Wednesday it will ask regulators to authorize its COVID-19 vaccine in children younger than 6 years old based on data showing it generated a similar immune response to adults in its clinical trial, Trend reports citing Reuters.
The Omicron variant of COVID-19 was predominant during Moderna's pediatric trial, and the drugmaker said two doses were around 38% effective in preventing infections in 2 to 5 year olds and 44% effective for children 6 months to under 2 years old.
It said these figures were consistent with the lower effectiveness against Omicron seen in adults who had received two doses of its vaccine.
Moderna's vaccine could be the first authorized shot for children under the age of 5 in the United States, and many parents of young children have been waiting on a vaccine.
--
Follow us on Twitter @AzerNewsAz
Here we are to serve you with news right now. It does not cost much, but worth your attention.
Choose to support open, independent, quality journalism and subscribe on a monthly basis.
By subscribing to our online newspaper, you can have full digital access to all news, analysis, and much more.
You can also follow AzerNEWS on Twitter @AzerNewsAz or Facebook @AzerNewsNewspaper
Thank you!